Welcome to our dedicated page for Lipocine news (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine stock.
Lipocine Inc. develops biopharmaceutical products using a proprietary technology platform for effective oral drug delivery. News about LPCN centers on clinical development of LPCN 1154, an oral brexanolone product candidate for postpartum depression, including trial progress, safety reviews and reported efficacy results.
Company updates also cover TLANDO, Lipocine’s oral testosterone replacement therapy, and related license, supply and distribution arrangements in multiple territories. Recurring financial news includes research and development spending, royalty revenue from TLANDO sales, pipeline prioritization and corporate presentations tied to the company’s oral-delivery programs.
Lipocine (NASDAQ: LPCN) reported its Q2 2022 financial results with a net loss of $2.6 million, improving from a loss of $6.8 million in Q2 2021. Revenues were $0.5 million from a non-refundable fee related to LPCN 1111. R&D expenses rose to $2.9 million due to ongoing studies, including LPCN 1148 and LPCN 1154. The company has $37.4 million in cash as of June 30, 2022, down from $46.6 million at year-end 2021. Key developments include the launch of TLANDO™ and progress with FDA-approved studies for LPCN 1144 and LPCN 2101.
Lipocine Inc. (NASDAQ: LPCN) announced that the FDA has accepted its IND application for LPCN 2101, a neuroactive steroid aimed at treating epilepsy in adults. The company plans to initiate a Phase 2 study focusing on photosensitive epilepsy to assess safety and efficacy. Dr. Mahesh Patel emphasized the potential of LPCN 2101 in addressing unmet medical needs in epilepsy management, particularly for women of childbearing age.
LPCN 2101 has shown a favorable pharmacokinetic profile and no concerning safety signals in preclinical studies.
Lipocine Inc. (NASDAQ: LPCN) has been granted two new US patents by the USPTO: 11,337,987 for compositions treating CNS disorders, and 11,370,811 for testosterone dodecanoate compositions. These patents support Lipocine's innovative treatment programs for liver and CNS disorders, as stated by Dr. Mahesh Patel, the company’s CEO. Lipocine's pipeline includes TLANDO, LPCN 1144, and LPCN 1107, targeting conditions like hypogonadism and non-cirrhotic NASH.
Lipocine Inc. (NASDAQ: LPCN) presented its novel oral positive GABAA modulator for epilepsy, LPCN 2101, at the 2022 Epilepsy Foundation Pipeline Conference. This product aims to address the unique needs of women with epilepsy of childbearing age, whose treatment options are currently limited. Pending FDA clearance, a proof-of-concept study is planned for the second half of 2022. The conference focuses on advancements in epilepsy treatment and encourages potential collaborations.
Lipocine Inc. (NASDAQ: LPCN) announced positive results from its Open Label Extension (OLE) study for LPCN 1144, an oral testosterone prodrug. The study, involving 25 subjects over 72 weeks, showed LPCN 1144 was well tolerated, with no safety signals reported. Key liver injury markers like ALT and AST were significantly reduced and maintained during treatment. Additionally, liver histology improvements support further development of LPCN 1144 as a treatment for Nonalcoholic Steatohepatitis (NASH). The company plans to discuss pivotal study design with the FDA.
Lipocine Inc. (NASDAQ: LPCN) announced its Q1 2022 financial results with a net loss of $3.5 million, consistent with the previous year. R&D expenses rose to $1.9 million due to ongoing clinical studies for LPCN 1148 and related projects. General and administrative costs decreased to $1.2 million. The company maintains $42 million in cash and equivalents, down from $46.6 million at the end of 2021. TLANDO™ received FDA approval with a commercial launch expected in Q2 2022, while Phase 2 studies for LPCN 1148 and LPCN 1144 are progressing.
Lipocine Inc. (NASDAQ: LPCN) announced the appointment of Jill M. Jene, Ph.D. and Spyros Papapetropoulos, M.D., Ph.D. to its board of directors on April 11, 2022. Dr. Jene brings over 20 years of biopharmaceutical experience, having facilitated over $6 billion in transactions. Dr. Papapetropoulos has a strong background in neuroscience and biopharmaceutical development. The company focuses on neuroendocrine and metabolic disorders, with a pipeline that includes products like TLANDO and LPCN 1148, targeting various conditions associated with testosterone deficiency and liver cirrhosis.
On March 29, 2022, Lipocine announced that its partner, Antares Pharma, received FDA approval for TLANDO™ (testosterone undecanoate), an oral testosterone replacement therapy for adult males with hypogonadism. This approval marks a significant milestone for Lipocine, which licensed the U.S. commercialization rights for TLANDO. The commercial launch is anticipated in Q2 2022, providing patients with a new, convenient treatment option. Lipocine continues to focus on developing innovative therapies for neuroendocrine and metabolic disorders while expanding its pipeline of drug candidates.
Lipocine Inc. (NASDAQ: LPCN) reported significant financial updates for the year ending December 31, 2021, including a net loss of $634,399, a reduction from a previous loss of $21 million. The company recognized $16.1 million in revenue, primarily from licensing fees related to TLANDO. R&D expenses decreased to $7.7 million, while general and administrative expenses fell to $5.3 million, mainly due to reduced legal and personnel costs. Lipocine also highlighted advancements in its clinical programs, including the initiation of a Phase 2 study for LPCN 1148 and an FDA-approved study for LPCN 1154.
Lipocine Inc. (NASDAQ: LPCN) announced positive FDA guidance regarding its drug LPCN 1144, aimed at treating nonalcoholic steatohepatitis (NASH) in non-cirrhotic men. The FDA confirmed that LPCN 1144 can be submitted via the 505(b)(2) pathway and that no additional nonclinical studies are necessary. Improvements were noted in NASH histopathology in phase 2 studies. The FDA suggested a phase 3 study duration of 72 weeks and requested updated protocols for review. CEO Dr. Mahesh Patel expressed satisfaction with the alignment on LPCN 1144's development plan.